• SENSEX
    NIFTY 50
Market

Tuesday's top brokerage calls: Pharma companies, HDFC Bank and more

Updated : 2020-07-14 09:16:37

Among brokerages, CLSA said the impact on the supply chain will hurt Q1 growth of pharma companies, while Macquarie has an 'outperform' call on HDFC Bank despite the recent developments. Here are the top brokerage calls for the day:

 CLSA on Pharma:  Impact on supply chain & generation will hurt Q1 growth and profitability, says CLSA.
CLSA on Pharma: Impact on supply chain & generation will hurt Q1 growth and profitability, says CLSA.
 Macquarie on HDFC Bank : The brokerage maintained 'outperform' call on the stock with a target of Rs 1,124. It said that senior management exits have no major impact for now. It expects RBI nod for the new CEO as early as the end of this month.
Macquarie on HDFC Bank: The brokerage maintained 'outperform' call on the stock with a target of Rs 1,124. It said that senior management exits have no major impact for now. It expects RBI nod for the new CEO as early as the end of this month.
 CLSA on Property:  Market share of top developers rose sharply over the last two quarters, said the brokerage. It lowered Godrej Properties and Oberoi Realty rating to 'outperform' from 'buy'.
CLSA on Property: Market share of top developers rose sharply over the last two quarters, said the brokerage. It lowered Godrej Properties and Oberoi Realty rating to 'outperform' from 'buy'.
 Citi on BHEL:  The brokerage downgraded the stock to 'sell' with a target of Rs 34. It said that high receivables continue to pressure cash flows and success in new areas will take time.
Citi on BHEL: The brokerage downgraded the stock to 'sell' with a target of Rs 34. It said that high receivables continue to pressure cash flows and success in new areas will take time.
 CLSA on Crompton Consumer:  The brokerage maintained a 'buy' call on the stock with a target at Rs 255 per share. The company reported a fourth straight year of expanding EBITDA margin, said CLSA, adding that it has a comprehensive plan to conserve cash & reduce cost.
CLSA on Crompton Consumer: The brokerage maintained a 'buy' call on the stock with a target at Rs 255 per share. The company reported a fourth straight year of expanding EBITDA margin, said CLSA, adding that it has a comprehensive plan to conserve cash & reduce cost.
 Nomura on Policy and Inflation:  Inflation spike portends pause in easing cycle, said the brokerage. It expects a pause in August policy to be followed by a 50 bps cut in Q4.
Nomura on Policy and Inflation: Inflation spike portends pause in easing cycle, said the brokerage. It expects a pause in August policy to be followed by a 50 bps cut in Q4.
Live TV

recommended for you

Ask Our Experts CNBC TV18

Advertisement